DE1131846B - Verfahren zur Inaktivierung von Poliomyelitisviren - Google Patents

Verfahren zur Inaktivierung von Poliomyelitisviren

Info

Publication number
DE1131846B
DE1131846B DEB55993A DEB0055993A DE1131846B DE 1131846 B DE1131846 B DE 1131846B DE B55993 A DEB55993 A DE B55993A DE B0055993 A DEB0055993 A DE B0055993A DE 1131846 B DE1131846 B DE 1131846B
Authority
DE
Germany
Prior art keywords
formaldehyde
inactivating
poliomyelitis
viruses
inactivation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DEB55993A
Other languages
German (de)
English (en)
Inventor
Dr Richard Haas
Dr Walter Henessen
Dr Rudolf Mauler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics GmbH Germany
Original Assignee
Behringwerke AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke AG filed Critical Behringwerke AG
Priority to DEB55993A priority Critical patent/DE1131846B/de
Priority to CH1412560A priority patent/CH399653A/de
Priority to GB43811/60A priority patent/GB949684A/en
Priority to SE12424/60A priority patent/SE309826B/xx
Priority to BE598471A priority patent/BE598471A/fr
Priority to FR856343A priority patent/FR1023M/fr
Publication of DE1131846B publication Critical patent/DE1131846B/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32661—Methods of inactivation or attenuation
    • C12N2770/32663—Methods of inactivation or attenuation by chemical treatment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DEB55993A 1959-12-22 1959-12-22 Verfahren zur Inaktivierung von Poliomyelitisviren Pending DE1131846B (de)

Priority Applications (6)

Application Number Priority Date Filing Date Title
DEB55993A DE1131846B (de) 1959-12-22 1959-12-22 Verfahren zur Inaktivierung von Poliomyelitisviren
CH1412560A CH399653A (de) 1959-12-22 1960-12-16 Verfahren zur Inaktivierung von Poliomyelitisviren
GB43811/60A GB949684A (en) 1959-12-22 1960-12-20 Process for inactivating poliomyelitis virus
SE12424/60A SE309826B (cs) 1959-12-22 1960-12-22
BE598471A BE598471A (fr) 1959-12-22 1960-12-22 Procédé pour rendre inactifs des virus de poliomyélite
FR856343A FR1023M (cs) 1959-12-22 1961-03-21

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DEB55993A DE1131846B (de) 1959-12-22 1959-12-22 Verfahren zur Inaktivierung von Poliomyelitisviren

Publications (1)

Publication Number Publication Date
DE1131846B true DE1131846B (de) 1962-06-20

Family

ID=6971173

Family Applications (1)

Application Number Title Priority Date Filing Date
DEB55993A Pending DE1131846B (de) 1959-12-22 1959-12-22 Verfahren zur Inaktivierung von Poliomyelitisviren

Country Status (6)

Country Link
BE (1) BE598471A (cs)
CH (1) CH399653A (cs)
DE (1) DE1131846B (cs)
FR (1) FR1023M (cs)
GB (1) GB949684A (cs)
SE (1) SE309826B (cs)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1042179B (de) * 1957-07-11 1958-10-30 Pasteur Institut Verfahren zur Herstellung antigenhaltiger Impfstoffe

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1042179B (de) * 1957-07-11 1958-10-30 Pasteur Institut Verfahren zur Herstellung antigenhaltiger Impfstoffe

Also Published As

Publication number Publication date
CH399653A (de) 1965-09-30
GB949684A (en) 1964-02-19
BE598471A (fr) 1961-06-22
SE309826B (cs) 1969-04-08
FR1023M (cs) 1961-12-26

Similar Documents

Publication Publication Date Title
DE2546166A1 (de) Gegerbte thrombozyten
DE2219635B2 (de) Insulinsalz-Protamin-Komplexe und Verfahren zu ihrer Herstellung
DE1924303A1 (de) AEthylaethylenimin als Inaktivierungsmittel
EP0543178A2 (de) Verfahren zur Herstellung eines virussicheren Thrombinkonzentrates
DE1924304C3 (de) Diäthylaminoäthyldextran (DEAE-D) als Adjuvans für Impfstoffe zur aktiven Immunisierung von Säugetieren
DE1131846B (de) Verfahren zur Inaktivierung von Poliomyelitisviren
DE69227805T2 (de) Verwendung von Tri-n-Butylphosphat bei niedrigem pH in Lösungen von biologisch aktiven Proteinen für eine verbesserte viruzide Wirkung
AT222274B (cs)
DE1492243C3 (de) Injizierbare Impfstoffe
DE2528584A1 (de) Verfahren zur inaktivierung der virusinfektiositaet unter gleichzeitiger stabilisierung von virusantigenen
DE68918649T2 (de) Lebende Newcastle-Krankheit-Virus-Vakzine.
EP0025116A1 (de) Verfahren zur Prüfung auf Inaktivierung von Impfstoffen und Unschädlichkeit von Blutprodukten sowie der Wirksamkeit von Chemotherapeutika bzw. Desinfektionsmitteln gegen Virushepatit und Verfahren zur Gewinnung von Virushepatitis-Antigen
DE2034118A1 (en) Xenogenic nucleic acids for enhancing antigenicity - of peptides and proteins
DE940315C (de) Verfahren zur Herstellung von Lymphe gegen Schweinepest
AT376883B (de) Verfahren zur inaktivierung von vermehrungsfaehigen krankheitserregern
AT376884B (de) Verfahren zur inaktivierung von vermehrungsfaehigen krankeitserregern
CH430052A (de) Verfahren zur Herstellung eines inaktivierten Pockenimpfstoffes
DE959048C (de) Verfahren zur Herstellung eines Impfstoffes zur aktiven Schutzimpfung gegen spinale Kinderlaehmung
DE1007473B (de) Verfahren zur Herstellung eines Poliomyelitis-Impfstoffes
AT200257B (cs)
DE1792050A1 (de) Verfahren zur Herstellung eines Mittels zur Bekaempfung von Geschwulstkrankheiten
DE513387C (de) Verfahren zum Schuetzen von Wolle, Pelzwerk u. dgl. gegen Mottenfrass
AT216142B (de) Verfahren zur Herstellung von Depotimpfstoffen
DE936232C (de) Verfahren zur Herstellung bestaendiger injizierbarer Loesungen von 4-Dimethylamino-1-phenyl-2, 3-dimethylpyrazolon
AT234275B (de) Verfahren zur Herstellung von Vaccinen aus Toxoiden bzw. Toxinen von Clostridium perfringens